Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872914 | 0.73 | KDM4E (0.30) | KDM4ELMNA | |
| SCHEMBL10000922 | 0.72 | — | — | |
| SCHEMBL10000921 | 0.72 | — | — | |
| SCHEMBL15133707 | 0.71 | KDM4E (0.35) | KDM4ELMNA | |
| SCHEMBL17120353 | 0.69 | KDM4E (0.36) | KDM4ELMNA | |
| SCHEMBL10000923 | 0.69 | KDM4E (0.34) | KDM4E | |
| SCHEMBL15923419 | 0.69 | KDM4E (0.32) | KDM4ELMNA | |
| SCHEMBL15132358 | 0.68 | — | — | |
| SCHEMBL15132365 | 0.68 | KDM4E (0.31) | KDM4E | |
| SCHEMBL3364098 | 0.68 | KDM4E (0.32) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2622960-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | Central Glass Company, Limited (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-2012043619-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | セントラル硝子株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | SEM1, CD81, VMA21 | KDM4E 3949/4885LMNA 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.